High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin

With strong 1-year returns and upside potential, Palvella Therapeutics, Inc. (NASDAQ:PVLA) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026.

On December 16, 2025, analyst confidence in Palvella Therapeutics, Inc. (NASDAQ:PVLA) was seen rising, as the company announced encouraging Phase 2 data for QTORIN rapamycin in cutaneous venous malformations (cVM).

The Fly reported that Palvella Therapeutics, Inc. (NASDAQ:PVLA) saw Canaccord analyst Whitney Ijem raise the firm’s target from $148 to $204, while reiterating a “Buy” rating. The analyst believes the better-than-expected improvement on the cVM-IGA at Week 12 should enable an efficient, lower-cost pivotal trial design. While management had targeted at least a 30% response rate, the firm noted that the improvement far exceeded expectations.

On the same day, Palvella Therapeutics, Inc. (NASDAQ:PVLA) also saw Truist raising its price target from $105 to $190, while maintaining a “Buy” rating. Incorporating risk-adjusted cVM sales into its model, the bank noted that the small proof-of-concept study meaningfully de-risked the opportunity. Additionally, Truist believes observed efficacy may not fully reflect the treatment effect, with responses appearing to deepen over time.

Palvella Therapeutics, Inc. (NASDAQ:PVLA) announced its positive topline Phase 2 TOIVA data on December 15, demonstrating broad clinical improvement and favorable tolerability.

On December 16, 2025, Palvella Therapeutics, Inc. (NASDAQ:PVLA) announced that the FDA granted Fast Track designation to QTORIN rapamycin for angiokeratomas. This regulatory win reinforces the company’s expanding development path and regulatory visibility.

Palvella Therapeutics, Inc. (NASDAQ:PVLA) is focused on developing novel topical therapies for serious, rare skin diseases. Its pipeline is led by the QTORIN platform, which targets conditions including venous malformations and angiokeratomas.

While we acknowledge the potential of EGO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Cheap Gold Stocks to Buy Now and 15 Best AI Stocks to Watch in December 2025.

Disclosure: None.